1. A prospective, comparative analysis of acute toxicity profile between three-dimensional conformal radiotherapy (3DCRT) and intensity-modulated radiotherapy (IMRT) in locally advanced head and neck cancer patients
- Author
-
Naresh Jakhotia, Nidhi Patni, Lalit Mohan Sharma, Anil Kumar Gupta, Dinesh Singh, Nilesh Kucha, Tej Prakash Soni, and Jaishree Goyal
- Subjects
Male ,Larynx ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,otorhinolaryngologic diseases ,medicine ,Carcinoma ,Mucositis ,Humans ,Prospective Studies ,RC254-282 ,Toxicity ,Head neck cancer ,Conformal radiotherapy ,business.industry ,Head and neck cancer ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Chemoradiotherapy ,Middle Aged ,medicine.disease ,Dysphagia ,Radiation therapy ,stomatognathic diseases ,Treatment Outcome ,medicine.anatomical_structure ,Oncology ,Head and Neck Neoplasms ,030220 oncology & carcinogenesis ,Nasogastric intubation ,Female ,Radiotherapy, Intensity-Modulated ,Radiology ,Radiotherapy, Conformal ,medicine.symptom ,business ,Compliance - Abstract
Introduction: The advances of modern radiotherapy have emerged with the development of conformal radiotherapy techniques, such as the three-dimensional conformal radiotherapy (3DCRT) and intensity-modulated radiotherapy (IMRT). We prospectively compared acute toxicities and treatment-compliance between IMRT and 3DCRT in patients with locally advanced head and neck carcinoma. Method: 80 patients were enrolled in this comparative prospective non-randomized study. Inclusion criteria were patients with locally advanced carcinoma of hypopharynx, oropharynx and larynx. 40 patients were treated with IMRT and 40 patients with 3DCRT to dose of 70 Gy in 35 fractions, along with concurrent cisplatin weekly chemotherapy. All patients were assessed weekly during chemoradiotherapy treatment and after 3 months of the treatment. Results: 15 patients (38.4%) versus 8 patients (20.51%) developed grade 3 mucositis in the 3DCRT and IMRT group respectively (p=
- Published
- 2020